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Abstract 
Introduction: Endometriosis is a disease defined by the presence of endometrial glands and stroma 
located outside the uterine cavity. These ectopic implants can be found throughout the pelvis, on and 
within the ovaries, abutting the uterine ligaments, occupying the rectovaginal septum, invading the 
intestinal serosa, and along the parietal peritoneum. Endometrial implantation at distant sites such as 
the pleura, lung, within surgical scars, and along the diaphragm also has been reported.
 (1).  It results 
often in subfertility and pain, occurs mainly in women of reproductive age (16–50 years) and has a 
progressive  character  in  at  least  50%,  but  the  rate  and  risk  factors  for  progression  are  unknown. 
Endometriosis  can  be  classified  into  four  stages:  minimal,  mild,  moderate  and  severe.  The  gold 
standard  for  the  diagnosis  of  endometriosis  is  laparoscopic  inspection,  ideally  with  histological 
confirmation.
  (2),  however,  is  an  invasive  technique  and  should  be  performed  only  after  imaging 
techniques  prove  insufficient  for  confident  diagnosis.
  (3)  Lack  of  a  non-invasive  diagnostic  test 
contributes to the long delay between onset of symptoms and diagnosis of endometriosis.
 (2) Additional 
tools  are  needed  for  non-invasive  classifications  in  order  to  reduce  the  number  of  unnecessary 
laparoscopies without adversely affecting outcomes. Finding specific and   more sensitive biomarkers 
in endometriosis is critical, because endometriosis is usually diagnosed only in advanced stages, and 
there is a high rate of morbidity for this disease. 
(4)   
Aim of the work: The aim of the current study is to assess the validity of serum and peritoneal high 
sensitivity CRP and TNF-alpha and plasma cell-free nuclear DNA (ccf nDNA) as biomarkers in early 
diagnosis of pelvic endometriosis. 
Methods: This study was conducted at the Obstetrics & Gynecology department, Maternity Hospital, 
Ain  Shams  University.  This  is  a  case  control  study  of  120  women  scheduled  for  diagnostic 
laparoscopy. Laparoscopy was indicated in these women whether for various causes of subfertility or 
for chronic pelvic pain between January 2011 and January 2012. The patients were divided into the 
following groups: Group I (endometriosis group/ study group) consisted of 80 patients diagnosed to 
have endometriosis during laparoscopy. Group I cases were subdivided into two subgroups, Group IA: 
consisted of 34 cases with stage 1or minimal endometriosis and Group IB: consisted of 46 cases with 
stage 2 or mild endometriosis. Group II (non-endometriosis group/Control group): consisted of 40 
cases with no detected pelvic pathology. During the laparoscopy procedure, both peripheral venous 
blood and peritoneal samples were withdrawn. Serum and peritoneal levels of high sensitivity CRP 
and TNF-alpha as well as plasma levels of ccf nDNA were compared in both groups and in early 
stages (minimal and mild) of endometriosis within the study group. 
Results:  Serum  TNF-a,  serum  hs-CRP  and  plasma  ccf  DNA  were  significantly  elevated  in  cases 
compared with the control group. They were also elevated in patients with group IA and group IB as 
compared to control group. However, there was no statistically significant difference between cases 
and  control  group  as  regards  peritoneal  TNF-a  and  peritoneal  hs-CRP.  There  was  no  significant 
difference between the group IA and group IB as regards all biomarkers. 
Conclusion: Our results showed that serum TNF-alpha , serum hs-CRP and plasma ccf DNA are 
highly reliable biomarkers for screening and early diagnosis of endometriosis,  but they  can not be 
used to discriminate between stage I and stage II. On the other hand, peritoneal TNF-a and peritoneal 
hs-CRP are non reliable for early diagnosis  of  endometriosis and can not be  used to discriminate 
between stage I and stage II of endometriosis. 
                    
INTRODUCTION 
 Endometriosis is a disease defined by 
the presence of endometrial glands and stroma 
located  outside  the  uterine  cavity.  These 
ectopic implants can be found throughout the 
pelvis, on and within the ovaries, abutting the 
uterine  ligaments, occupying the rectovaginal 
septum,  invading  the  intestinal  serosa,  and 
along  the  parietal  peritoneum.  Endometrial 
implantation at distant sites such as the pleura, Diagnostic Validity of Serum and Peritoneal TNF-alpha… 
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lung,  within  surgical  scars,  and  along  the 
diaphragm also has been reported (1).  
 It results often in subfertility and pain, 
occurs mainly  in  women  of reproductive age 
(16–50 years) and has a progressive character 
in at least 50%, but the rate and risk factors for 
progression  are  unknown.  Endometriosis  can 
be classified  into four stages:  minimal,  mild, 
moderate and severe. The gold standard for the 
diagnosis  of  endometriosis  is  laparoscopic 
inspection,  ideally  with  histological 
confirmation  (2),  however,  is  an  invasive 
technique and should be performed only after 
imaging  techniques  prove  insufficient  for 
confident diagnosis (3). 
 Lack of a non-invasive diagnostic test 
contributes to the long delay between onset of 
symptoms and diagnosis of endometriosis. (2) 
Additional  tools  are  needed  for  non-invasive 
classifications in order to reduce the number of 
unnecessary  laparoscopies  without  adversely 
affecting  outcomes.  Finding  specific  and   
more sensitive biomarkers in endometriosis is 
critical,  because  endometriosis  is  usually 
diagnosed only in advanced stages, and there is 
a high rate of morbidity for this disease (4).  
Development  of  a  non-invasive 
diagnostic test for endometriosis would have a 
groundbreaking impact on the patients’ quality 
of life, on the efficacy of available treatment as 
well as on the cost of endometriosis (2). 
A  non-invasive  diagnostic  test  could 
be developed in circulation or menstrual fluid 
based on the pathology of endometriosis, such 
as immune  function, cell-death  event and,  or 
inflammatory  reactions  in  the  patients  with 
endometriosis (4). 
TNF-a,  a  secretory  product  of 
activated macrophages, is a potent inducer of 
new blood vessel growth, besides stimulating 
the proliferation of endometriotic stromal cells 
(5). 
Serum  C-reactive  protein  (CRP), 
which is a protein  of the acute inflammatory 
phase, is widely used as a marker of ongoing 
inflammation in clinical practice. (6) 
 The discovery of circulating cell-free 
(ccf)  DNA  in  circulation  has  opened  up  the 
possibilities  of  non-invasive  diagnosis  and 
monitoring of a wide variety of inflammatory 
conditions,  such  as  systemic  lupus 
erythematosus and rheumatoid arthritis. (7) 
 
THE AIM OF THE WORK 
The  aim  of  the  current  study  is  to 
assess the validity of serum and peritoneal high 
sensitivity  CRP  and  TNF-alpha  and  plasma 
cell-free  nuclear  DNA  (ccf  nDNA)  as 
biomarkers  in  early  diagnosis  of  pelvic 
endometriosis. 
 METHODS  
This  is  a  case  control  study  of  120 
women  scheduled  for  diagnostic  laparoscopy 
at  Ain  Shams  University  Maternity  Hospital. 
Laparoscopy  is  indicated  in  these  women 
whether for various causes of subfertility or for 
chronic pelvic pain between January 2011 and 
January 2012.  
Inclusion criteria were:  
reproductive age (between 23 and 43 years). 
regular menstrual cycles. 
Exclusion criteria were:  
-age >45 years 
-patients  with  known  history  of  any 
malignancy 
-patients with overt stage 3 or 4 endometriosis 
-patients with overt infection.  
 
The  purposes  and  procedures  of  the 
study  was  explained  to  all  eligible  women 
before  recruitment  in  the  study.  Included 
women  were  asked  to  sign  an  informed 
consent before participating in the study. 
These  patients  were  subjected  to  the 
following: full  history,  general  and  abdominal 
examination,  local  pelvic  examination  and 
laparoscopic  visualization  of  presence  or 
absence of endometriosis. 
All  laparoscopy  procedures  were 
performed  in  the  proliferative  phase  of  the 
cycle.  The  abdomen  and  pelvis  were 
systematically  inspected  for  signs  of 
endometriosis.  Women  who  showed  positive 
signs for minimal or mild endometriosis (grade 
1 and 2) were staged according to the ASRM 
classification (1997), and categorized as group 
I  (Study  or  Endometriosis  Group).  Group  I 
cases  were  subdivided  into  two  subgroups: 
Group  IA  s  with  stage  1or  minimal 
endometriosis  and  Group  IB  with  stage  2  or 
mild endometriosis. 
These  women  with  laparoscopically 
diagnosed endometriosis had a biopsy from the 
endometriotic  lesions  for  Histopathological 
confirmation.All  other  women  who  were 
laparoscopically free of signs of endometriosis 
were categorized as group II (Control Group). 
During  the  laparoscopy  procedure,  both 
peripheral  venous  blood  and  peritoneal 
samples  were  withdrawn.  Concentration  of 
TNF-alpha  was  measured  by  ELISA  using 
Orgenium Laboratories’ human TNF-alpha kits 
.Concentration  of  high  sensitivity  CRP  was 
measured  by  automated  assays.DNA  was Ahmed F Koura et al  
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extracted using the commercially available kits 
for real time multiplex PCR in Egypt. 
Serum  and  peritoneal  levels  of  high 
sensitivity  CRP  and  TNF-alpha  as  well  as 
plasma levels of ccf nDNA were compared in 
both groups and in early stages (minimal and 
mild) of endometriosis within the study group. 
 
RESULTS 
The  mean age among  cases; Group I 
patients  was  27.7  yrs±  3.76.The  youngest 
patient was 21 years old and the oldest was 39 
years old. The mean age for cases with stage 1 
endometriosis was 24.4 ± 3.18, for cases with 
stage  2  endometriosis  was  27.8  ±  4.16.The 
mean age for control group; Group II was 30.1 
± 7.42. 
 
The  mean  Body  mass  Index  (BMI) 
among  cases;  Group  I  patients  was  26.33± 
3.39.The  mean  BMI  for  cases  with  stage  1 
endometriosis  was  25.82  ±  2.96  ,  for  cases 
with stage 2 endometriosis was 26.71  ±  3.567 
.The  mean  BMI  for  control  group;  Group  II 
was 26.28 ± 3.83. 
 
Tables  1-4  show  description  of  personal  and 
lab data among cases (Group I endometriosis), 
Group I A; Stage 1 Endometriosis, Group I b; 
stage  2  Endometriosis  and  among  control 
group (Group II) 
 
 
Table (1): Description of personal and lab data among cases; Group I endometriosis: 
 
Cases  Minimum  Maximum  Mean  ±SD 
Age  (years)  21.00  39.00  27.70  3.76 
BMI (kg/m2)  20.34  32.45  26.33  3.39 
Serum TNF  
(pg/ml)  100.00  491.00  285.23  107.01 
Peritoneal TNF 
(pg/ml)  110.00  988.00  158.51  39.60 
Serum hsCRP 
(ng/ml)  1.00  8.50  2.10  1.86 
Peritoneal hsCRP 
(ng/ml)  0.80  2.50  0.86  0.38 
Plasma ccf. DNA  
(genome equivalent/ml)  3600.00  93000.00  25196.38  20443.18 
 
 
Table (2): Description of personal and lab data among Group I A; Stage 1 Endometriosis 
 
 
Minimum  Maximum  Mean  ±SD 
Age (years)  22.00  39.00  27.47  3.18 
BMI (kg/m2)  21.58  31.26  25.82  2.96 
Serum TNF 
(pg/ml)  100.00  350.00 
147.38  65.69 
Peritoneal TNF 
(pg/ml)  110.00  461.00 
151.32  110.28 
Serum hsCRP 
(ng/ml)  1.00  6.00 
2.08  1.31 
Peritoneal hsCRP 
(ng/ml)  0.80  2.50 
0.78  0.40 
Plasma ccf. DNA 
(genome equivalent/ml)  3600.00  34000.00 
5944.71  2192.97 
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Minimum  Maximum  Mean  ±SD 
Age (years)  21.00  39.00  27.87  4.16 
BMI(kg/m2)  20.34  32.45  26.71  3.67 
Serum TNF 
(pg/ml)  190.00  491.00  242.76  89.11 
Peritoneal TNF 
(pg/ml)  190.00  988.00  177.35  95.74 
Serum hsCRP 
(ng/ml)  1.60  8.50  2.10  2.06 
Peritoneal hsCRP 
(ng/ml)  1.20  2.50  0.83  0.36 
Plasma ccf. DNA 
(genome equivalent/ml)  3600.00  93000.00 
 
7108.48 
 
2975.59 
 
Table (4): Description of personal and lab data among controls; Group II 
Control  Minimum  Maximum  Mean  ±SD 
Age (years)  22.00  44.00  30.10  7.42 
BMI (kg/m2)  21.02  31.44  26.28  3.83 
Serum TNF 
(pg/ml)  50.00  200.00  102.75  36.71 
Peritoneal TNF 
(pg/ml)  80.00  300.00  146.25  43.70 
Serum hsCRP 
(ng/ml)  0.40  2.99  1.27  0.60 
Peritoneal hsCRP 
(ng/ml)  0.10  1.50  0.74  0.40 
Plasma ccf. DNA 
(genome equivalent/ml)  1090.00  9180.00  4903.00  2172.44 
Student T Test was used to assess the statistical significance of the difference between two study 
group means.  
  P- value: level of significance 
-P>0.05: Non significant (NS). 
-P< 0.05: Significant (S). 
            -P<0.01: Highly significant (HS) 
 
Table (5): Comparison between cases (Group I) and controls (Group II) as regard personal and lab 
findings 
Parameters 
Patients  Control  t-test  sig 
Mean  ±SD  Mean  ±SD  t  p-value   
Age (years)  27.70  3.76  30.10  7.42  -2.356  0.060  NS 
BMI (kg/m2)  26.33  3.39  26.28  3.83  0.072  0.090  NS 
Serum TNF 
(pg/ml)  285.23  107.01  102.75  36.71  10.462  <0.001 
HS 
Peritoneal TNF 
(pg/ml)  158.51  39.60  146.25  43.70  1.544  0.125 
NS 
Serum hsCRP 
(ng/ml)  2.10  1.86  1.27  0.60  2.747  0.021 
S 
Peritoneal hsCRP 
(ng/ml)  0.86  0.38  0.74  0.40  1.602  0.111 
NS 
Plasma ccf. DNA 
(genome 
equivalent/ml)  25196.38  20443.18  4903.00  2172.44  6.248  <0.001 
HS 
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Fig 1: Bar graph shows the difference between Serum TNF among Cases and Control Group.  
 
 
 
 
 
 
 
 
 
 
 
Fig 2: Bar graph shows the difference between serum hs-CRP among Cases and Control Group.  
 
Table (6): Comparison between Group IA and controls as regard personal and lab findings 
Parameters 
Control  Minimal  t-test  sig 
Mean  ±SD  Mean  ±SD  t  p-value   
Age (years)  30.10  7.42  27.47  3.18  1.920  0.059  NS 
BMI (kg/m2)  26.28  3.83  25.82  2.96  0.575  0.567  NS 
Serum TNF 
(pg/ml)  102.75  36.71  147.38  65.69  -3.322  0.023 
S 
Peritoneal TNF 
(pg/ml)  146.25  43.70  151.32  70.28  -0.382  0.703 
NS 
Serum hsCRP 
(ng/ml)  1.27  0.60  2.08  1.31  -7.808  0.044 
S 
Peritoneal hsCRP 
(ng/ml)  0.74  0.40  0.78  0.40  -0.435  0.664 
NS 
Plasma ccf. DNA 
(genome equivalent/ml)  4903.00  2172.44 
5944.71  2192.97 
-2.047  0.044 
S Diagnostic Validity of Serum and Peritoneal TNF-alpha… 
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Fig 3: Bar graph shows the difference between Plasma ccf DNA among Group IA (Stage 1 
endometriosis) and Control Group.  
 
Table (7): Comparison between Group IB and controls as regard personal and lab findings 
Parameters 
Control  Mild  t-test  sig 
Mean  ±SD  Mean  ±SD  t  p-value   
Age (years)  30.10  7.42  27.87  4.16  1.748  0.084  NS 
BMI (kg/m2)  26.28  3.83  26.71  3.67  -0.530  0.598  NS 
Serum TNF 
(pg/ml)  102.75  36.71  242.76  89.11  -15.893  <0.001 
HS 
Peritoneal TNF 
(pg/ml)  146.25  43.70  177.35  95.74  -1.852  0.068 
NS 
Serum hsCRP 
(ng/ml)  1.27  0.60  2.10  2.06  -2.438  0.017 
S 
Peritoneal hsCRP 
(ng/ml)  0.74  0.40  0.83  0.36  -0.961  0.339 
NS 
Plasma ccf. DNA 
(genome equivalent/ml)  4903.00  2172.44 
7108.48  2975.59 
-2.178  0.013 
S 
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 Fig 4  :Bar graph shows the difference between Serum TNF among Group IB (Stage 2 endometriosis) 
and Control Group.  
 
Table (8): Comparison between minimal and mild cases as regard personal and lab findings 
Parameters 
Minimal  Mild  t-test  sig 
Mean  ±SD  Mean  ±SD  t  p-value   
Age (years)  27.47  3.18  27.87  4.16  -0.467  0.642  NS 
BMI (kg/m2)  25.82  2.96  26.71  3.67  -1.166  0.247  NS 
Serum TNF 
(pg/ml) 
147.38  65.69  242.76  89.11  -5.341  0.051 
NS 
Peritoneal TNF 
(pg/ml) 
151.32  110.28  177.35  95.74  -1.127  0.263 
NS 
Serum hsCRP 
(ng/ml) 
2.08  1.31  2.10  2.06  0.050  0.960 
NS 
Peritoneal hsCRP 
(ng/ml) 
0.78  0.40  0.83  0.36  -0.586  0.559 
NS 
Plasma ccf. DNA 
(genome equivalent/ml) 
5944.71  2192.97  7108.48  2975.59  -1.925  0.057 
NS 
 
Table (9): ROC Curve to discriminate between cases and controls using tested markers 
Test markers 
(cutoff points) 
AUC  (95% CI)  Sensitivity  Specificity  PPV  NPV  P  Sig 
Serum TNF 
≥165  0.88  80.3  98.5  95.0  86.2  77.6  97.2  0.026  S 
Peritoneal 
TNF≥180  0.92  83.0  99.2  87.0  76.7  80.9  97.3  0.050  NS 
Serum 
hsCRP≥1.5 
0.83  87.7  97.3  85.0  93.7  87.2  92.6  0.021  S 
Peritoneal 
hsCRP≥1.00  0.91  61.5  89.1  77.5  98.7  96.9  89.8  0.033  S 
Plasma ccf. 
DNA≥5950.  0.89  86.8  99.6  97.5  71.2  62.9  98.3  <0.001  HS 
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Fig 5: ROC curve for Serum TNF, Peritoneal TNF, serum hsCRP, peritoneal hsCRP and plasma ccf 
DNA to discriminate between cases and controls.  
 
 
 
Table (10):ROC Curve to discriminate between minimal and mild cases using tested markers  
 
 
Test markers 
(cutoff points)  AUC  (95% CI)  Sensitivity  Specificity  PPV  NPV  P  Sig 
Serum TNF 
≥286  0.87  0.784  0.940  76.1  82.4  85.4  71.8  0.074  NS 
Peritoneal 
TNF≥426  0.86  0.767  0.929  71.7  84.1  97.3  71.1  0.063  NS 
Serum 
hsCRP≥4.6  0.65  0.542  0.759  47.8  91.2  88.0  56.4  0.068  NS 
Peritoneal 
hsCRP≥1.2  0.57  0.455  0.681  91.3  23.5  61.8  66.7  0.282  NS 
Plasma ccf. 
DNA≥22900  0.85  0.762  0.926  69.6  97.1  97.0  70.2  0.024  S 
 
Fig 6: ROC curve for Serum TNF, Peritoneal TNF, serum hsCRP, peritoneal hsCRP and plasma ccf 
DNA to discriminate cases with stage 1 from cases with stage 2.  
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DISCUSSION 
 
Endometriosis  is  estimated  to  affect 
10–15% of women of reproductive age and is 
characterized  by  the  presence  of  functional 
endometrial  glands  and  stroma  outside  the 
uterine cavity, resulting in chronic pelvic pain, 
dysmenorrhoea,  dyspareunia  and  infertility; 
this leads to a considerable burden in terms of 
health care costs and the quality of life (8) 
 
The diagnosis of endometriosis can be 
suspected  in  women  with  pelvic  pain  and/or 
subfertility,  although  endometriosis  may  be 
completely  asymptomatic  (9).Clinical 
detection of abdominal or pelvic pain can be 
suggestive  of  endometriosis.  Vaginal 
ultrasound is an adequate diagnostic method to 
detect ovarian endometriotic cysts and deeply 
infiltrative endometriotic noduli, but does not 
rule  out  peritoneal  endometriosis  or 
endometriosis-associated  adhesions.  The  gold 
standard for the diagnosis of endometriosis is 
laparoscopic  inspection,  ideally  with 
histological confirmation (2) 
 
Because  laparoscopy  is  an  invasive 
procedure,  the  diagnosis  of  endometriosis  is 
often delayed for an average of 11.7 years in 
patients with pelvic pain and for 3.5 years in 
patients with infertility (10). It was found that 
the  younger  the  patient  is  at  onset  of  the 
symptoms,  the  longer  it  takes  before  an 
endometriosis  diagnosis  is  made  (11).  This 
delay may result in social and/or work-related 
problems  for  the  patient,  in  addition  to 
increased  anxiety  and  fear  of  having  a  more 
serious condition (10) 
 
Development  of  a  non-invasive 
diagnostic test for endometriosis would have a 
groundbreaking impact on the patients’ quality 
of life, on the efficacy of available treatment as 
well as on the cost of endometriosis (2). 
   
The aim of our study was to assess the 
validity  of  serum  and  peritoneal  high 
sensitivity  CRP  and  TNF-  alpha  and  plasma 
cell-free  nuclear  DNA  (ccf  nDNA)  as 
biomarkers  in  early  diagnosis  of  pelvic 
endometriosis.  
 
In our study, serum TNF-levels were 
significantly  elevated  in  women  with 
endometriosis  compared  with  controls.  (P  < 
0.001)    Serum  TNF-a  levels  were  also 
significantly  elevated  in  women  with stage 1 
and  stage  2  endometriosis  compared  with 
controls.  Comparing  serum  TNF-levels 
between  women  with  stage  1  and  stage  2 
endometriosis,  there  was  no  statistically 
significant difference (P>0.05). 
 
Foda and Abdel Aal (12) performed a 
study on a total of 95 women who underwent 
laparoscopy  were  divided  into  two  groups: 
control  cases  (30  cases)  with  no  pathologic 
ﬁndings;  and  endometriosis  patients  (65 
cases);subdivided  into stages 1–2 or minimal–
mild (MM) and stages 3–4 or moderate–severe 
(MS)  cases.  They  measured  serum  and 
peritoneal  levels  of  IL-6,  CA-125,  TNF-a, 
HsCRP  and  VEGF.  In  agreement  with  our 
results, Serum TNF-a levels were signiﬁcantly 
higher  in  women  with  endometriosis  when 
compared with the controls (P < 0.001). Serum 
TNF-a  were  significantly  elevated  in  women 
with MM endometriosis when compared with 
the  control  cases  (P  <  0.001)  and  with  MS 
endometriosis  (P  <  0.006  &  P  <  0.03 
respectively).  
In  our  study,  using  ROC  curve 
analysis , Serum TNF had a cut off point  of 
165 pg/ml to discriminate cases from controls, 
with a sensitivity of  95 %, specificity of 86.2 
%  positive predictive value of 77.6, negative 
predictive value of 97.2 with diagnostic AUC 
of 0.88. Serum TNF had a cut off point of 286 
pg/ml to discriminate cases with stage 1 from 
cases with stage 2, with a sensitivity of 76.1 %, 
specificity of 82.4% positive predictive value 
of 85.4, negative predictive value of 71.8 with 
diagnostic AUC of 0.87. 
 
By  using  ROC  curve  analysis  in  the 
study by Foda and Abdel Aal (12), the serum 
TNF-a  optimal  threshold  value  of  >12.45 
pg/ml  was  found  to  be  able  to  diagnose 
endometriosis  with  a  sensitivity,  specificity, 
diagnostic  accuracy  &  AUC  of  89.23%, 
86.87%, 86.67% & 0.89respectively. 
 
In the current study, Peritoneal TNF-
a  levels  were  not  significantly  elevated  in 
women  with  endometriosis  compared  with 
controls.  Peritoneal  TNF-a  levels  were  also 
non significantly elevated in women with stage 
1  and  stage  2  endometriosis  compared  with 
controls.  Comparing  peritoneal  TNF-a  levels 
between  women  with  stage  1  and  stage  2 
endometriosis, there was also a no significant 
difference P>0.05: Non significant (NS). Diagnostic Validity of Serum and Peritoneal TNF-alpha… 
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Our  results  came  in  disagreement 
with a study the study by  Foda and Abdel Aal 
(12),  which  showed    a  marked  elevation  in 
TNF-a  level  which  was  apparent  in  the 
Peritoneal fluid of patients with endometriosis, 
with a higher  value  in Minimal-Mild than  in 
Moderate-Severe endometriosis (P < 0.001).  
 
In  the  current  study,  we  found  a 
significant difference in serum Hs-CRP levels 
in  the  endometriosis  group  when  compared 
with  the  non-endometriosis  group  (P<  0.05). 
Serum Hs-CRP levels  were also significantly 
elevated  in  women  with  stage  1  and  stage  2 
endometriosis  compared  with  controls. 
Comparing  serum  Hs-CRP  levels  between 
women with stage 1 and stage 2 endometriosis, 
there  was  also  no  significant  difference 
(P>0.05; Non significant ). 
 
In  agreement  with  our  findings,  the 
study by Foda and Abdel Aal (12) reported that 
there was a high serum Hs-CRP levels in the 
endometriosis group when compared with the 
non-endometriosis  group  (P  <0.001).  In  their 
study,  Moderate  -  severe  endometriosis  had 
significantly  higher  levels  than  Minimal-
Moderate  endometriosis  (P  <  0.001).This 
finding indicated that Hs-CRP cannot be used 
for  early  diagnosis  of  endometriosis.  These 
findings  were in agreement with the findings 
of Lermann et al.  (6). 
Our  results  did  not  agree  with  the 
study by Lermann et al.  (6) which  found no 
significant  difference  in  CRP  and  hs-CRP 
levels in women with histologically confirmed 
endometriosis  in  comparison  with  the  other 
groups  of  women.  Neither  hs-CRP  nor  CRP 
appeared  to  be  advantageous  markers  for 
predicting  the  presence  of  endometriosis  in 
that study. There was no association between 
hs-CRP and CRP levels and the stage  of the 
disease  in  their  study.  Their  results  are  in 
accordance with those reported by Xavier et al. 
(5),  who  found  no  statistically  significant 
differences  between  women  with 
endometriosis and controls for serum levels of 
CRP.  
 
In  our  study,  using  ROC  curve 
analysis, Serum hsCRP had a cut off point of 
1.5 ng/ml to discriminate cases from controls, 
with  a  sensitivity  of    85  %,  specificity  of 
93.7%    positive  predictive  value  of  87.2, 
negative  predictive  value  of  92.6  with 
diagnostic AUC of 0.83. Serum hsCRP had a 
cut off point of 4.6 ng/ml to discriminate cases 
with stage 1 from cases with stage 2, with a 
sensitivity  of  47.8  %,  specificity  of  91.2%  
positive  predictive  value  of  88.0,  negative 
predictive value of 56.4 with diagnostic AUC 
of 0.65. 
 
In our study, we found no significant 
difference  between  controls  and  cases 
regarding  peritoneal  level  of  hs-CRP. 
Similarly,  we  found  no  significant  difference 
between controls and cases  with stage 1 and 
stage  2  endometriosis  regarding  peritoneal 
level  of  hs-CRP.  Moreover,  there  was  no 
significant  difference  between  the  peritoneal 
level of hs CRP among cases with stage 1 and 
cases  with  stage  2  endometriosis;  P  value 
>0.05; Non significant (NS). 
 
In the current study, using ROC curve 
analysis, Peritoneal TNF had a cut off point of 
180 pg/ml to discriminate cases from controls, 
with a sensitivity of  87 %, specificity of 76.7 
%  positive predictive value of 80.9, negative 
predictive value of 97.3 with diagnostic AUC 
of 0.92.Peritoneal TNF had a cut off point of 
426  pg/ml  to  discriminate  cases  from  with 
stage  1  from  cases  with  stage  2,  with  a 
sensitivity  of    71.7  %,  specificity  of    84.1%  
positive  predictive  value  of  97.3,  negative 
predictive value of 71.1 with diagnostic AUC 
of 0.86. 
In  our  study,  we  analysed  the 
concentrations  of  plasma  ccf  DNA  in  the 
patients  and controls and investigated whether 
the  circulating  species  could  be  potential 
biomarkers  for  developing  a  non-invasive 
diagnostic test for the disease. 
 
We  found  a  highly  significant 
difference regarding plasma ccf  DNA between 
controls and cases (P<0.01; highly significant ) 
as  well  as  a  significant  difference  between 
controls  and  stage  1&  2  endometriosis. 
However, the difference between patients with  
stage  1  and  stage  2    was  not  statistically 
significant.  (P  value  >0.05;  Non  significant 
(NS). 
 
 Our results came in agreement with a 
study by Zachariah et al. (4), which reported 
significantly  increased  concentrations  of  ccf 
nDNA  in  plasma  from  patients  with 
endometriosis compared with the age-matched 
controls.  It  corresponded  with  the  results  of 
different  inflammatory  diseases  presenting 
elevated ccf nDNA in plasma, which reflects Ahmed F Koura et al  
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the increased frequency of cell-death events in 
the conditions (7). 
The  clinical  relevance  of  using  the 
plasma ccf  nDNA as a marker to distinguish 
between  the  minimal  or  mild  disease  and 
healthy  controls  was  evaluated  by  ROC 
analysis. Plasma ccf DNA had a cut off point 
of  5950  to  discriminate  cases  from  controls, 
with  a  sensitivity  of    97.5  %,  specificity  of  
71.2%    positive  predictive  value  of  62.9, 
negative  predictive  value  of  98.3  with 
diagnostic AUC of 0.89. Plasma ccf DNA had 
a cut off point of 22900 to discriminate cases 
with stage 1 from cases with stage 2, with a 
sensitivity  of    69.6  %,  specificity  of  97.1%  
positive  predictive  value  of  97.0,  negative 
predictive value of 70.2 with diagnostic AUC 
of 0.85 
CONCLUSION 
Our  results  showed  that  serum  TNF-
alfa , serum hs-CRP and plasma ccf DNA are 
highly  reliable  biomarkers  for  screening  and 
early diagnosis of endometriosis,  but they  can 
not be used to discriminate between stage I and 
stage II. On the  other  hand, peritoneal TNF-
alpha and peritoneal hs-CRP are non reliable 
for  early  diagnosis  of  endometriosis  and  can 
not be used to discriminate between stage I and 
stage II of endometriosis. 
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